Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C127123
http://purl.obolibrary.org/obo/NCIT_C127123
Preferred Name

Emapalumab
Definitions
A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system; its upregulation is associated with certain auto-immune and auto-inflammatory diseases in which the immune system is abnormally activated.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system; its upregulation is associated with certain auto-immune and auto-inflammatory diseases in which the immune system is abnormally activated.
prefLabel
Emapalumab
label
Emapalumab
NCI_META_CUI
CL507913
PDQ_Closed_Trial_Search_ID
780986
code
C127123
Has_Target
prefixIRI
NCIT:C127123
in_subset
Display_Name
Emapalumab
Preferred_Name
Emapalumab
FDA_UNII_Code
3S252O2Z4X
Contributing_Source
CTRP
FDA
Maps_To
Emapalumab
CAS_Registry
1709815-23-5
NCI_Drug_Dictionary_ID
780986
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
780986
Accepted_Therapeutic_Use_For
primary hemophagocytic lymphohistiocytosis (HLH)
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display